What is the predictive value of the Reflux Impact Scale - PREDICT

Study identifier:NL401611

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

What is the value of the use of validated questionnaire (Reflux Impact Scale) for predicting treatment success with PPI

Medical condition

Gastroesophageal Reflux Disease

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

938

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Oct 2007
Primary Completion Date: -
Study Completion Date: 01 Jun 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2008 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria